| Quarterly Financials | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 188 | 208 | 190 | 189 | 192 | 237 | 213 | 215 | 251 | 267 | 259 | 223 | 275 | 286 | 270 | 243 | 289 | 327 | 308 | 277 | 350 | 360 | 333 | 309 | 395 | 461 | 420 | 398 | 461 | 504 | 488 | 562 | 717 | 744 | 726 | 711 | 775 | 793 | 801 | 755 | 871 |
| Expenses | 109 | 125 | 112 | 135 | 114 | 152 | 128 | 141 | 162 | 164 | 159 | 153 | 170 | 175 | 190 | 171 | 189 | 205 | 203 | 184 | 223 | 220 | 210 | 209 | 269 | 309 | 286 | 284 | 297 | 324 | 311 | 403 | 470 | 477 | 477 | 453 | 496 | 504 | 543 | 484 | 577 |
| EBITDA | 79 | 83 | 78 | 54 | 78 | 86 | 85 | 75 | 88 | 103 | 100 | 70 | 105 | 111 | 81 | 72 | 100 | 122 | 105 | 93 | 127 | 141 | 123 | 100 | 125 | 151 | 134 | 114 | 164 | 180 | 177 | 160 | 248 | 267 | 249 | 258 | 279 | 289 | 258 | 270 | 294 |
| Operating Profit % | 40 % | 37 % | 39 % | 27 % | 39 % | 34 % | 38 % | 32 % | 34 % | 37 % | 36 % | 28 % | 38 % | 38 % | 28 % | 30 % | 34 % | 37 % | 33 % | 33 % | 35 % | 38 % | 36 % | 31 % | 31 % | 32 % | 32 % | 28 % | 35 % | 35 % | 36 % | 26 % | 34 % | 35 % | 34 % | 36 % | 36 % | 36 % | 32 % | 36 % | 34 % |
| Depreciation | 5 | 5 | 6 | 7 | 5 | 5 | 7 | 9 | 7 | 8 | 10 | 11 | 12 | 12 | 13 | 14 | 10 | 11 | 11 | 12 | 15 | 15 | 17 | 18 | 23 | 29 | 30 | 35 | 41 | 42 | 46 | 54 | 76 | 81 | 81 | 77 | 71 | 69 | 70 | 70 | 72 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 8 | 7 | 6 | 5 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 3 | 9 | 17 | 16 | 18 | 33 | 60 | 60 | 57 | 54 | 49 | 50 | 49 | 46 | 47 |
| Profit Before Tax | 73 | 78 | 72 | 48 | 74 | 99 | 77 | 62 | 78 | 92 | 89 | 58 | 95 | 103 | 72 | 62 | 95 | 116 | 99 | 85 | 117 | 131 | 109 | 85 | 101 | 121 | 107 | 76 | 113 | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 | 145 | 159 | 180 |
| Tax | 11 | 8 | 4 | 1 | 3 | 6 | 3 | 6 | 6 | 7 | 9 | 4 | 11 | 10 | 9 | 5 | 6 | 8 | 9 | 17 | 10 | 12 | 8 | 5 | 8 | 2 | 6 | 14 | 19 | 4 | 14 | -3 | 26 | 33 | 29 | 27 | 36 | 38 | 37 | -120 | 36 |
| Net Profit | 63 | 69 | 68 | 47 | 71 | 93 | 75 | 56 | 72 | 86 | 80 | 54 | 84 | 93 | 64 | 56 | 89 | 108 | 90 | 68 | 107 | 118 | 101 | 80 | 93 | 119 | 100 | 62 | 94 | 122 | 102 | 80 | 90 | 96 | 87 | 102 | 125 | 135 | 109 | 279 | 143 |
| EPS in ₹ | 45.64 | 5.02 | 4.95 | 3.43 | 5.15 | 6.75 | 5.43 | 4.06 | 5.18 | 6.20 | 5.83 | 3.93 | 6.11 | 6.74 | 4.62 | 4.13 | 6.56 | 7.93 | 6.64 | 5.03 | 7.86 | 8.71 | 7.41 | 5.91 | 6.96 | 8.84 | 7.49 | 4.81 | 6.97 | 9.08 | 7.55 | 5.22 | 6.11 | 6.73 | 6.16 | 6.90 | 8.66 | 8.82 | 7.32 | 20.60 | 10.28 |
Eris Lifesciences
Eris Lifesciences
1,321.70
+18.20
(1.40%)
Market Cap
18,314.43 Cr
PE Ratio
27.14
Volume
69,111.00
Day High - Low
1,332.20 - 1,301.00
52W High-Low
1,799.00 - 1,200.00
There are new updates from the company1 day ago
View
Key Fundamentals
Market Cap
18,314.43 Cr
EPS
45.33
PE Ratio
27.14
PB Ratio
4.63
Book Value
281.61
EBITDA
1,127.90
Dividend Yield
0.55 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
16.62
Debt to Equity
0.97
Analyst Rating and Forecast
- By Refinitiv from11 analysts
Actual
Company News
View All News
Eris Lifesciences submitted its Business Responsibility and Sustainability Report for FY26, detailing environmental metrics, workforce data, and governance disclosures. The filing covers standalone operations across India.
Eris Lifesciences board approves reappointment of Sujesh Vasudevan as independent director for five years. The company also schedules its 20th AGM for September 25, 2026.
Eris Lifesciences to meet analysts on August 27Aug 24, 2026
Eris Lifesciences has scheduled a meeting with analysts and investors on August 27 at 10:30 am, signalling an upcoming engagement with the investment community.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,899.00 | #1 4,55,633.71 | 37.70 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 44.62 | |
9,100.00 | 2,41,576.41 | 83.91 | 11,067.00 | 13.95 | 2,568 | 65.50 | 65.13 | |
4,857.00 | 1,84,744.67 | 86.89 | 13,886.20 | 20.34 | 2,138 | 3.28 | 44.72 | |
1,120.00 | 1,12,698.21 | 24.65 | 27,657.90 | 17.64 | 5,026 | -34.90 | 45.48 | |
1,385.00 | 1,11,886.58 | 33.44 | 29,044.60 | 2.24 | 3,870 | -39.18 | 36.26 | |
1,840.00 | 99,333.61 | 92.77 | 6,867.80 | 22.01 | 890 | #1 123.93 | 54.21 | |
2,110.00 | 96,476.07 | #1 17.59 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 25.94 | |
2,327.90 | 96,141.33 | 46.84 | 14,636.40 | 14.85 | 1,938 | 29.13 | 38.69 | |
1,151.00 | 96,070.41 | 30.28 | 35,058.60 | 3.90 | 4,158 | -69.10 | 38.91 | |
1,653.10 | 95,115.72 | 25.23 | 34,145.20 | 5.56 | 3,503 | 25.21 | 54.82 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
7.73 %
Net Income Growth
72.80 %
Cash Flow Change
119.13 %
ROE
45.15 %
ROCE
23.39 %
EBITDA Margin (Avg.)
1.10 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,041 | 7,036 | 7,366 |
| Fixed Assets | 65 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,307 | 5,188 |
| Current Assets | 237 | 216 | 299 | 582 | 480 | 467 | 627 | 765 | 2,302 | 1,226 | 1,540 |
| Capital Work in Progress | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 172 |
| Investments | 144 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 62 |
| Other Assets | 190 | 192 | 324 | 435 | 595 | 685 | 807 | 1,041 | 2,686 | 1,596 | 1,945 |
| Total Equity & Liabilities | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,041 | 7,036 | 7,366 |
| Current Liabilities | 71 | 76 | 226 | 306 | 165 | 167 | 200 | 443 | 2,532 | 1,385 | 2,077 |
| Non Current Liabilities | 25 | 60 | 349 | 79 | 91 | 91 | 164 | 1,003 | 1,286 | 2,380 | 1,393 |
| Total Equity | 302 | 591 | 886 | 1,169 | 1,296 | 1,576 | 1,908 | 2,221 | 3,222 | 3,272 | 3,896 |
| Reserve & Surplus | 302 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,894 | 2,182 | 2,573 | 2,841 | 3,889 |
| Share Capital | 0 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 | 106 |
| Investing Activities | -92 | -44 | -185 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 | -78 |
| Operating Activities | 90 | 132 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 |
| Financing Activities | 1 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 | -881 |
Share Holding
| % Holding | Jan 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 55.55 % | 54.13 % | 52.69 % | 52.68 % | 52.66 % | 52.66 % | 52.30 % | 52.29 % | 52.70 % | 52.86 % | 52.86 % | 54.91 % | 54.90 % | 54.90 % | 54.88 % | 54.87 % | 54.86 % | 54.85 % | 54.83 % | 54.85 % | 54.85 % | 53.92 % | 54.14 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 13.20 % | 0.00 % | 14.27 % | 14.59 % | 8.01 % | 8.35 % | 8.43 % | 8.40 % | 7.21 % | 6.85 % | 6.39 % | 5.75 % |
| DIIs | 10.52 % | 9.25 % | 9.66 % | 9.57 % | 9.99 % | 10.11 % | 10.36 % | 10.38 % | 9.94 % | 10.02 % | 10.28 % | 14.53 % | 13.86 % | 15.63 % | 16.23 % | 18.64 % | 18.06 % | 18.07 % | 18.17 % | 19.36 % | 20.32 % | 20.35 % | 20.72 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 22.42 % | 23.28 % | 23.23 % | 23.29 % | 23.19 % | 23.14 % | 21.34 % | 21.27 % | 21.45 % | 21.66 % | 22.07 % | 15.47 % | 15.67 % | 14.24 % | 13.53 % | 10.51 % | 9.29 % | 9.16 % | 9.12 % | 9.12 % | 8.51 % | 10.06 % | 10.10 % |
| Others | 11.51 % | 13.34 % | 14.42 % | 14.46 % | 14.16 % | 14.09 % | 16.01 % | 16.07 % | 15.90 % | 15.46 % | 14.79 % | 1.90 % | 15.57 % | 0.95 % | 0.77 % | 7.96 % | 9.43 % | 9.49 % | 9.47 % | 9.45 % | 9.48 % | 9.26 % | 9.29 % |
| No of Share Holders | 29,195 | 41,470 | 46,477 | 49,833 | 54,223 | 57,061 | 51,639 | 48,055 | 46,746 | 45,931 | 44,169 | 42,245 | 46,496 | 51,753 | 44,176 | 46,346 | 53,314 | 50,087 | 52,225 | 59,438 | 54,713 | 51,656 | 50,798 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 2.87 | 5.5 | 6.01 | 7.35 | 0.00 | 7.35 | 7.21 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.47 | 0.8 | 1.05 | 0.87 | 0.00 | 0.57 | 0.55 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 Sept 2026 |  Annual General Meeting | NA | 25 Sept 2026 | 1,317.10 | 1,303.85 |
| 06 Aug 2021 |  Dividend | ₹ 6.01 /share | 05 Aug 2021 | 742.15 | 747.90 |
| 16 Aug 2022 | Dividend | ₹ 7.35 /share | 11 Aug 2022 | 696.65 | 695.05 |
| 25 Sept 2024 | Annual General Meeting | NA | 25 Sept 2024 | 1,454.55 | 1,311.75 |
| 25 Oct 2024 |  Quarterly Result Announcement | NA | 25 Oct 2024 | 1,329.15 | 1,283.80 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,157.90 | 1,249.75 |
| 13 Feb 2025 | Dividend | ₹ 7.35 /share | 13 Feb 2025 | 1,460.10 | 1,301.85 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 1,402.05 | 1,465.15 |
| 25 Jul 2025 | Annual General Meeting | NA | 25 Jul 2025 | 1,679.60 | 1,785.30 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 1,791.20 | 1,801.10 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 1,599.60 | 1,595.20 |
| 13 Feb 2026 | Quarterly Result Announcement | NA | 13 Feb 2026 | 1,412.95 | 1,510.40 |
| 20 May 2026 | Quarterly Result Announcement | NA | 20 May 2026 | 1,374.90 | 1,336.20 |
| 29 May 2026 | Dividend | ₹ 7.21 /share | 29 May 2026 | 1,336.20 | 1,350.80 |
| 29 Jul 2026 | Quarterly Result Announcement | NA | 29 Jul 2026 | 1,440.60 | 1,390.80 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication2 days ago
2 days agoBusiness Responsibility and Sustainability Reporting (BRSR)2 days ago
2 days agoReg. 34 (1) Annual Report.2 days ago
2 days agoAnnual General Meeting Of The Company Scheduled On September 25 20262 days ago
2 days agoBoard Meeting Outcome for Outcome For Board Meeting4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 24, 2026
Aug 24, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2026
Aug 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 10, 2026
Aug 10, 2026Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Availing Working Capital Term Loan From Axis BankAug 06, 2026
Aug 06, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 04, 2026
Aug 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2026
Jul 30, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 30, 2026
Jul 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 29, 2026
Jul 29, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJul 29, 2026
Jul 29, 2026Financial Results For The Quarter Ended June 30 2026Jul 29, 2026
Jul 29, 2026Board Meeting Outcome for Outcome Of Board MeetingJul 29, 2026
Jul 29, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2026
Jul 23, 2026Board Meeting Intimation for Consideration And Approval Of The Financial Results For The Period Ended June 30 2026Jul 23, 2026
Jul 23, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2026
Jul 09, 2026Closure of Trading WindowJun 26, 2026
Jun 26, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 26, 2026
Jun 26, 2026Corporate PresentationJun 23, 2026
Jun 23, 2026Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD Jun 08, 2026
Jun 08, 2026Imposition Of Fine By BSE Limited And National Stock Exchange Of India LimitedMay 28, 2026
May 28, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2026
May 27, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 26, 2026
May 26, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMay 25, 2026
May 25, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMay 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Date of payment of DividendMay 20, 2026
May 20, 2026Corporate Action-Board approves DividendMay 20, 2026
May 20, 2026Financial Results For The Quarter And Financial Year Ended March 31 2026May 20, 2026
May 20, 2026Board Meeting Outcome for Outcome Of Board MeetingMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 15, 2026
May 15, 2026Board Meeting Intimation for Consideration Of Financial Results And Interim DividendMay 15, 2026
May 15, 2026Credit Rating Of Eris Threpeutics LimitedMay 12, 2026
May 12, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 11, 2026
May 11, 2026Announcement under Regulation 30 (LODR)-Credit RatingMay 08, 2026
May 08, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 24, 2026
Apr 24, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotApr 23, 2026
Apr 23, 2026INSPECTION OF SWISS PARENTERALS UNITS 1 AND 2 BY HALMED CROATIAApr 20, 2026
Apr 20, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2026
Apr 10, 2026Closure Of The Transaction Related To Acquisition Of Probiotics Business Of Velbiom Probiotics Private Limited.Mar 31, 2026
Mar 31, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Corporate GuaranteeMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 20, 2026
Mar 20, 2026Board Meeting Outcome for The Meeting Held Today I.E. March 20 2026Mar 20, 2026
Mar 20, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 37.00
ATR(14)
Volatile 35.55
STOCH(9,6)
Neutral 23.47
STOCH RSI(14)
Neutral 23.40
MACD(12,26)
Bearish -1.59
ADX(14)
Strong Trend 30.68
UO(9)
Bearish 36.45
ROC(12)
Downtrend And Accelerating -3.45
WillR(14)
Neutral -63.39
About Eris Lifesciences
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands...more
Listing Date
29 Jun, 2017(9 Years, 2 Months, 6 Days)
Website
Chairperson NameAmit Indubhushan Bakshi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
